Understanding the efficacy variables of an HIV vaccine trial
Lancet Infect Dis
.
2012 Jul;12(7):499-500.
doi: 10.1016/S1473-3099(12)70117-2.
Epub 2012 May 30.
Author
José Esparza
1
Affiliation
1
Global Health Program, Bill and Melinda Gates Foundation, Seattle, WA 98102, USA. Jose.Esparza@Gatesfoundation.org
PMID:
22652343
DOI:
10.1016/S1473-3099(12)70117-2
No abstract available
Publication types
Comment
MeSH terms
AIDS Vaccines / therapeutic use*
Female
HIV Infections / prevention & control*
Humans
Male
Risk-Taking*
Substances
AIDS Vaccines
AIDSVAX
AIDSVAX B-E